Revolutionizing Cancer Therapy: Unleashing the Power of MET Inhibitors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 2365
Special Issue Editor
Special Issue Information
Dear Colleagues,
We would like to discuss the HGF-MET signaling pathway, which involves the interaction between the Mesenchymal Epithelial Transition Factor (MET) receptor and its ligand, the Hepatocyte Growth Factor (HGF). This pathway plays a crucial role in various cellular processes, such as cell proliferation, motility, morphogenesis, angiogenesis, and tissue regeneration. Dysregulation of the MET signaling system is associated with various malignancies.
MET-TKI inhibitors, as agents targeting the MET-HGF signaling pathway, have shown promising results in various cancer types with resistance to conventional chemotherapy. Continuous research findings have been reported, demonstrating their efficacy in cancer subtypes resistant to first-line treatment. Beyond second-line regimens, studies are also exploring the use of MET inhibitors in neoadjuvant and combination regimens for multiple cancer types, with ongoing research anticipated in the future.
In this Special Issue, we aim to focus on the promising target agent, MET inhibitors, and invite contributions from multidisciplinary expert groups engaged in research related to targeting the MET-HGF signaling pathway for various cancer treatments. This Special Issue seeks to present studies that apply next-generation sequencing (NGS) technology to the development of target agents, not only contributing to the treatment of lung cancer, but also exploring the potential for diverse cancer types, including gastric cancer, hepatocellular carcinoma, and pancreatic cancer.
We believe that this Special Issue will make significant contributions to the development of promising therapies for various cancer types, utilizing MET-TKI inhibitors as a potential targeted therapy. We welcome research papers that explore the efficacy and safety of MET inhibitors, and we anticipate that this Special Issue will foster advancements in the field of oncology and inspire future investigations in cancer treatment.
We invite researchers and experts to submit their original research, reviews, and for consideration in this Special Issue. Together, we can advance the understanding and application of MET inhibitors in cancer treatment and contribute to the development of innovative therapies for various malignancies.
Prof. Dr. Sang Hyub Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epithelial–mesenchymal transition
- mesenchymal–epithelial transition
- MET gene mutation
- MET exon14 skipping
- hepatocyte growth factor
- tumor microenvironment
- savolitinib
- crizotinib
- cabozatinib
- tepotinib
